Medical Care Technologies Inc.

OTCPK:MDCE Stock Report

Market Cap: US$5.6m

Medical Care Technologies Valuation

Is MDCE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MDCE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MDCE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MDCE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MDCE?

Key metric: As MDCE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MDCE. This is calculated by dividing MDCE's market cap by their current revenue.
What is MDCE's PS Ratio?
PS Ratio8.6x
SalesUS$616.38k
Market CapUS$5.63m

Price to Sales Ratio vs Peers

How does MDCE's PS Ratio compare to its peers?

The above table shows the PS ratio for MDCE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1x
KDLY Kindly MD
2.2xn/aUS$5.8m
NIVF NewGenIvf Group
1xn/aUS$5.2m
CMAX CareMax
0.004x26.0%US$2.5m
SYRA Syra Health
0.8xn/aUS$6.5m
MDCE Medical Care Technologies
8.6xn/aUS$5.6m

Price-To-Sales vs Peers: MDCE is expensive based on its Price-To-Sales Ratio (8.6x) compared to the peer average (1x).

Price to Sales Ratio vs Industry

How does MDCE's PS Ratio compare vs other companies in the US Healthcare Industry?

30 CompaniesPrice / SalesEstimated GrowthMarket Cap
MCK McKesson
0.2x8.1%US$79.75b
CVS CVS Health
0.2x4.6%US$71.86b
COR Cencora
0.2x6.4%US$48.16b
CNC Centene
0.2x5.5%US$30.47b
MDCE 8.6xIndustry Avg. 1.0xNo. of Companies30PS012345+
30 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MDCE is expensive based on its Price-To-Sales Ratio (8.6x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is MDCE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MDCE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MDCE's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Elevance Health

US$93.6b

Operates as a health benefits company in the United States.

ELV

US$402.55

7D

0.5%

1Y

-15.9%

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.37

7D

5.1%

1Y

-18.8%

electroCore

US$64.0m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.21

7D

2.5%

1Y

101.6%